ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 124

Socioeconomic-Demographic, Disease Activity, Treatment and Immunologic Variables Affect B Cell Subtypes in Systemic Lupus Erythematosus

Arlene Bravo1, Michelle T. Ngo2, Michael De Vera3, Karina Marianne D. Torralba2,4 and Abigail Benitez2,4, 1Internal Medicine, Loma Linda University, Loma Linda, CA, 2Rheumatology, Loma Linda University, Loma Linda, CA, 3Transplant Surgery, Loma Linda University, Loma Linda, CA, 4Transplantation Institute, Loma Linda University, Loma Linda, CA

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: B cells, belimumab and health disparities, SLE

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Sunday, November 13, 2016

Session Title: Healthcare Disparities in Rheumatology - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: B cell subset proportions within the B cell pool, also known as B cell signatures (BCS), reflect not only systemic lupus erythematosus (SLE) disease activity status, but also therapy effects. In this study, we evaluated whether socioeconomic-demographic, disease activity, immunologic, and treatment factors, may influence BCS in SLE patients.

Methods: Peripheral blood mononuclear cells were isolated from 37 patients who fulfilled the ACR Classification criteria for SLE, and from 14 healthy individuals. Socioeconomic-demographic (age, ethnicity, primary language, highest level of education, health insurance), disease activity (duration, SLEDAI score), and immunologic variables (parity, anti-dsDNA), as well as type of treatment received (standard of care therapy (SCT) vs Belimumab), were collected. B cell subsets (nonmemory =T1, T2, Follicular Mature (FM); memory =IgM, IgM/IgD, IgD, switched) were identified via flow cytometry. Student T-Test, one-way ANOVA, Dunnett’s and Tukey’s post-hoc tests were used for statistical analyses.

Results: Ethnicity, race, age, level of education, and primary language do not alter B cell subsets in SLE patients. SLE patients with either HMO-private or federal health insurance have less T1 subsets as compared to those with HMO-public insurance (p = 0.0004). SLE patients with either HMO-private or federal insurance have more FM subsets as compared to SLE patients with HMO-public insurance (p = 0.0041). Both T2 (p = 0.0030) and IgD (p = 0.0389) subsets from SLE patients with SLEDAI score 1-5 were lower as compared to healthy controls. Patients with SLE duration of disease from 0-5 or 6-10 years have lower T2 subsets as compared to healthy controls (p = 0.0020). Patients with SLE duration from 0-5 years have higher FM subsets as compared to healthy controls (p = 0.036). SLE patients have lower proportions of T2 subsets, irrespective of the presence or absence of anti-dsDNA, as compared to healthy controls (p = 0.0052). The presence of anti-dsDNA is associated with lower IgD subsets as compared to healthy controls (p = 0.0204). SLE patients with children have lower T1 (p = 0.0326) and higher FM (p = 0.0448) subsets as compared to those with none. SLE patients treated with SCT have lower T1 subsets as compared to those treated with both SCT and Belimumab (p = 0.0303). SLE patients treated with either SCT or Belimumab have lower T2 cells as compared to healthy controls (p = 0.0102). SLE patients treated with SCT have lower switched B cells as compared to those treated with both SCT and Belimumab (p = 0.0064). SLE patients treated with both SCT and Belimumab have higher switched B cells as compared to healthy controls (p = 0.0064).

Conclusion: To our knowledge, this is the first study showing that socioeconomic-demographic, disease activity, and immunologic variables are associated with unique B cell profiles in SLE patients.


Disclosure: A. Bravo, None; M. T. Ngo, None; M. De Vera, None; K. M. D. Torralba, GlaxoSmithKline, 9,ACR, USSONAR, 9; A. Benitez, None.

To cite this abstract in AMA style:

Bravo A, Ngo MT, De Vera M, Torralba KMD, Benitez A. Socioeconomic-Demographic, Disease Activity, Treatment and Immunologic Variables Affect B Cell Subtypes in Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/socioeconomic-demographic-disease-activity-treatment-and-immunologic-variables-affect-b-cell-subtypes-in-systemic-lupus-erythematosus/. Accessed January 16, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/socioeconomic-demographic-disease-activity-treatment-and-immunologic-variables-affect-b-cell-subtypes-in-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.